Table 4 Cardiovascular data
|  | N | Whole group, N = 177 | CSA group, N = 105 | OSA group, N = 36 | TECSA group, N = 36 | P |
|---|---|---|---|---|---|---|
Existence of cardiac disease, n (%) | 177 | 134 (75.71) | 81 (77.14) | 26 (72.22) | 27 (75.00) | 0.833 |
 Ischaemic HF | 175 | 61 (34.86%) | 37 (35.58%) | 11 (31.43%) | 13 (36.11%) | 0.891 |
 Non Ischaemic HF | 175 | 43 (24.57%) | 26 (25.00%) | 9 (25.71%) | 8 (22.22%) | 0.931 |
 Valvulopathy | 175 | 13 (7.43%) | 4 (3.85%)c | 6 (17.14%)c | 3 (8.33%) | 0.025 |
 History of AF | 174 | 53 (30.46%) | 32 (31.07%) | 11 (31.43%) | 10 (27.78%) | 0.925 |
 Other cardiac disease | 175 | 33 (18.86%) | 18 (17.31%) | 4 (11.43%) | 11 (30.56%) | 0.098 |
Cardiological monitoring | ||||||
 Cardiological consultation, n (%) | 151 | 147 (97.35%) | 89 (95.70%) | 26 (100.00%) | 32 (100.00%) | 0.467 |
 Delay since the last consultation (days)a | 147 | 183 [70–365] | 188.0 [80.0–365] | 117.5 [24–262] | 214.5 [125–470] | 0.070 |
 Cardiological echocardiography, n (%) | 148 | 145 (97.97%) | 89 (97.80%) | 25 (100.00%) | 31 (96.88%) | 1.000 |
 Delay since the last echocardiography (days)a | 145 | 263 [116–529] | 266c [113–541] | 175d [28–356] | 315cd [172–665] | 0.015 |
Hemodynamic parameters a | ||||||
 Systolic BP (mmHg) | 149 | 130 [118–140] | 130.0 [119.0–140.0] | 130.0 [111.0–40.00] | 131.0 [114.0–147.0] | 0.740 |
 Diastolic BP (mmHg) | 149 | 75 [70–82] | 75.00 [70.00–80.00] | 78.50 [66.00–85.00] | 74.00 [70.00–85.00] | 0.937 |
 Heart Rhythm (bpm) | 155 | 70 [62–77] | 70.00 [62.00–76.00] | 68.00 [60.00–78.00] | 70.00 [63.00–77.00] | 0.876 |
 LVEF, n (%) | 177 |  |  |  |  | < 0.001 |
  Reduced (LVEF ≤45%) |  | 13 (7.34%) | 0 (0.00%)bc | 8 (22.22%)c | 5 (13.89%)b |  |
  Normal |  | 164 (92.6%) | 105 (100.00%) | 28 (77.78%) | 31 (86.11%) |  |
Treatment, n (%) | ||||||
 Diuretic | 168 | 73 (43.45%) | 39 (37.14%) | 18 (56.25%) | 16 (51.61%) | 0.097 |
 Spironolactone | 166 | 19 (11.45%) | 12 (11.65%) | 4 (12.50%) | 3 (9.68%) | 1.000 |
 ACE inhibitor | 168 | 61 (36.31%) | 36 (34.29%) | 13 (40.63%) | 12 (38.71%) | 0.771 |
 β-receptor blocker | 168 | 64 (38.10%) | 38 (36.19%) | 12 (37.50%) | 14 (45.16%) | 0.663 |
 ARB | 165 | 35 (21.21%) | 24 (23.53%) | 7 (21.88%) | 4 (12.90%) | 0.446 |
 Calcium blocker | 169 | 38 (22.49%) | 23 (21.90%) | 11 (33.33%) | 4 (12.90%) | 0.144 |
 Cardiac glycoside | 168 | 2 (1.19%) | 2 (1.90%) | 0 (0.00%) | 0 (0.00%) | 1.000 |
 Antiarrhythmic drug | 168 | 24 (14.29%) | 12 (11.43%) | 6 (18.75%) | 6 (19.35%) | 0.326 |
 Antiagregants | 168 | 45 (26.79%) | 25 (23.81%) | 8 (25.00%) | 12 (38.71%) | 0.250 |
 Anticoagulant | 168 | 37 (22.02%) | 22 (20.95%) | 8 (25.00%) | 7 (22.58%) | 0.887 |
 Pacemaker | 175 | 22 (12.57%) | 12 (11.54%) | 4 (11.43%) | 6 (16.67%) | 0.664 |
 ICD | 175 | 7 (4.00%) | 0 (0%)bc | 3 (8.57%)c | 4 (11.11%)b | 0.002 |
Hospitalization during the preceding year | ||||||
 Patients with at least one hospitalization for any cause, n (%) | 177 | 37 (20.90%) | 19 (18.10%) | 7 (19.44%) | 11 (30.56%) | 0.276 |
 Patients with at least one hospitalization for a cardiologic cause, n (%) | 177 | 11 (6.21%) | 5 (4.76%) | 3 (8.33%) | 3 (8.33%) | 0.509 |